Imunon, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. The filing covers the unaudited quarter ended March 31, 2024. Imunon is a clinical-stage biotechnology company developing non-viral DNA therapeutics and vaccines. Its lead candidate, IMNN-001, is in Phase II development for advanced ovarian cancer; IMNN-101 is a COVID-19 booster vaccine candidate. The company reported no significant revenue and does not expect product-sales revenue in the next several years, if ever.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | No significant revenue reported | No significant revenue reported |
| Research and development expense | $3.29 million | $2.62 million |
| General and administrative expense | $1.72 million | $3.06 million |
| Total operating expenses | $5.01 million | $5.68 million |
| Net loss | $4.93 million; $0.52 per share | $5.59 million; $0.68 per share |
| Net cash used in operating activities | $5.87 million | $3.98 million |
| Cash, cash equivalents and short-term investments | Approximately $9.8 million, including interest receivable | Approximately $15.7 million at December 31, 2023, including interest receivable |
| Working capital | $7.3 million | $10.8 million at December 31, 2023 |
| Total liabilities | $5.83 million | $8.53 million at December 31, 2023 |
There is no meaningful revenue-based margin to report. Cash and cash equivalents alone were $2.35 million at quarter-end, with $7.46 million of available-for-sale debt securities. The company reported $1.51 million of operating lease liabilities. The SVB loan facility was repaid in full in 2023; no loan-facility interest expense was recorded in Q1 2024.
Material changes versus the prior comparable period
- Net loss narrowed by approximately $0.66 million, primarily as G&A expense declined 44%, partly offset by a 26% increase in R&D expense.
- R&D spending rose as clinical and regulatory costs increased and PLACCINE vaccine development expense grew to $1.22 million from $1.02 million. G&A declined mainly due to lower stock-based compensation, legal, employee-related and consulting costs.
- Operating cash use increased by approximately $1.89 million. The filing reports a $2.71 million decrease in accounts payable and accrued liabilities as a significant operating cash-flow factor.
- Cash and investments declined from approximately $15.7 million at year-end to $9.8 million. There were no ATM share sales in Q1 2024; Q1 2023 ATM sales generated approximately $2.47 million net proceeds.
Outlook, management commentary and risks
- Management expects available cash resources to fund operations into the fourth quarter of 2024 and states that substantial doubt exists about the company’s ability to continue as a going concern. There are no committed sources of additional capital. Management plans to pursue equity or debt financing, partnerships, collaborations, licensing and spending reductions; success is not assured.
- OVATION 2, a Phase I/II study of IMNN-001, completed enrollment at 113 patients in 2022. Preliminary 2023 results suggested a progression-free-survival trend and approximately nine months’ improvement in overall survival for the treatment arm; the company expected topline results in mid-2024. These findings are preliminary, and some subgroup analyses were not prespecified.
- In the IMNN-001/bevacizumab study, four patients had been enrolled in the Phase I portion as of March 31, 2024. The company reported that FDA clearance to begin a Phase I study of IMNN-101 was received on April 18, 2024, after the quarter; enrollment was expected to begin in Q2 2024. The planned study is to enroll 24 healthy adults.
- Key risks include clinical and regulatory uncertainty, patient enrollment, the need to raise capital and potential dilution, competition, and the possibility that trials or development costs diverge from expectations. The company reported no material change to the risk factors in its 2023 Form 10-K.
- A derivative shareholder lawsuit concerning alleged statements about ThermoDox remains pending. The company intends to contest it; the likelihood and amount of any loss cannot currently be determined.
Important facts for investors to verify
- Whether OVATION 2 topline results were reported as expected and how final efficacy and safety data compare with the preliminary trends.
- Whether IMNN-101 enrollment began in Q2 2024 and what safety and immunogenicity data show.
- Actual cash burn, updated runway and the availability, timing, terms and dilution impact of financing or partnership arrangements.
- Enrollment progress and subsequent results for the IMNN-001/bevacizumab study, and developments in the shareholder litigation.